Cell Biotech Past Earnings Performance
Past criteria checks 1/6
Cell Biotech's earnings have been declining at an average annual rate of -17.8%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 0.8% per year. Cell Biotech's return on equity is 5.6%, and it has net margins of 11.7%.
Key information
-17.8%
Earnings growth rate
-15.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -0.8% |
| Return on equity | 5.6% |
| Net Margin | 11.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio
May 05
Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?
Mar 18A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns
Feb 25Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend
Feb 04
Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?
Jan 14Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend
Dec 24Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Dec 13Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years
Nov 18Revenue & Expenses BreakdownBeta
How Cell Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 53,787 | 6,304 | 29,845 | 3,725 |
| 30 Sep 23 | 52,751 | 166 | 30,941 | 3,544 |
| 30 Jun 23 | 51,509 | 2,736 | 29,847 | 3,457 |
| 31 Mar 23 | 51,272 | 8,128 | 26,595 | 3,510 |
| 31 Dec 22 | 50,526 | 8,281 | 25,278 | 3,559 |
| 30 Sep 22 | 48,754 | 14,642 | 23,407 | 3,712 |
| 30 Jun 22 | 49,081 | 12,997 | 22,932 | 3,627 |
| 31 Mar 22 | 48,328 | 10,632 | 22,284 | 3,677 |
| 31 Dec 21 | 46,873 | 10,383 | 21,987 | 3,500 |
| 30 Sep 21 | 45,761 | 6,032 | 22,512 | 3,181 |
| 30 Jun 21 | 44,196 | 3,270 | 23,576 | 3,207 |
| 31 Mar 21 | 44,156 | 2,942 | 24,165 | 3,243 |
| 31 Dec 20 | 45,582 | 3,189 | 24,641 | 3,329 |
| 30 Sep 20 | 46,990 | 5,900 | 24,787 | 3,800 |
| 30 Jun 20 | 46,333 | 6,472 | 24,345 | 3,856 |
| 31 Mar 20 | 46,582 | 8,017 | 23,826 | 3,673 |
| 31 Dec 19 | 45,960 | 7,231 | 23,697 | 3,704 |
| 30 Sep 19 | 49,346 | 11,379 | 22,796 | 3,421 |
| 30 Jun 19 | 53,473 | 13,585 | 22,518 | 3,419 |
| 31 Mar 19 | 58,136 | 16,544 | 22,454 | 3,362 |
| 31 Dec 18 | 62,544 | 19,384 | 22,435 | 3,433 |
| 30 Sep 18 | 60,324 | 16,525 | 22,830 | 3,369 |
| 30 Jun 18 | 61,301 | 17,865 | 22,970 | 3,271 |
| 31 Mar 18 | 62,295 | 19,802 | 21,916 | 3,156 |
| 31 Dec 17 | 61,057 | 18,198 | 21,497 | 2,886 |
| 30 Sep 17 | 62,706 | 20,756 | 22,242 | 2,908 |
| 30 Jun 17 | 58,937 | 18,581 | 20,885 | 2,880 |
| 31 Mar 17 | 57,150 | 17,071 | 19,618 | 2,945 |
| 31 Dec 16 | 58,276 | 18,499 | 20,097 | 2,918 |
| 30 Sep 16 | 55,048 | 17,719 | 16,941 | 3,047 |
| 30 Jun 16 | 57,418 | 21,705 | 16,464 | 3,064 |
| 31 Mar 16 | 55,230 | 20,603 | 17,162 | 2,838 |
| 31 Dec 15 | 49,505 | 17,505 | 15,602 | 2,844 |
| 30 Sep 15 | 49,291 | 16,582 | 17,259 | 2,386 |
| 30 Jun 15 | 44,997 | 12,474 | 16,274 | 2,303 |
| 31 Mar 15 | 41,350 | 10,329 | 14,321 | 2,257 |
| 31 Dec 14 | 40,768 | 10,403 | 14,076 | 2,057 |
| 30 Sep 14 | 39,111 | 9,929 | 12,343 | 2,027 |
| 30 Jun 14 | 36,560 | 8,879 | 11,838 | 1,775 |
| 31 Mar 14 | 34,823 | 8,998 | 11,131 | 1,718 |
| 31 Dec 13 | 31,598 | 7,800 | 10,233 | 1,916 |
| 30 Sep 13 | 27,687 | 6,604 | 9,199 | 1,862 |
| 30 Jun 13 | 27,269 | 5,976 | 9,474 | 1,889 |
Quality Earnings: A049960 has high quality earnings.
Growing Profit Margin: A049960's current net profit margins (11.7%) are lower than last year (16.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A049960's earnings have declined by 17.8% per year over the past 5 years.
Accelerating Growth: A049960's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A049960 had negative earnings growth (-23.9%) over the past year, making it difficult to compare to the Biotechs industry average (28.8%).
Return on Equity
High ROE: A049960's Return on Equity (5.6%) is considered low.